{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:43:55Z","timestamp":1789533835869,"version":"build-2803163510"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T00:00:00Z","timestamp":1442534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0137834","type":"journal-article","created":{"date-parts":[[2015,9,18]],"date-time":"2015-09-18T15:00:19Z","timestamp":1442588419000},"page":"e0137834","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial"],"prefix":"10.1371","volume":"10","author":[{"given":"Katherine A.","family":"Sutherland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris M.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kapaata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Lyagoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontiano","family":"Kaleebu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"Gilks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Goodall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moira","family":"Spyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Kityo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deenan","family":"Pillay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DART Virology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,9,18]]},"reference":[{"key":"ref1","unstructured":"WHO. HIV\/AIDS Fact sheet Geneva, Switzerland: WHO; 2015 [Accessed 28 July 2015]. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.who.int\/mediacentre\/factsheets\/fs360\/en\/\" xlink:type=\"simple\">http:\/\/www.who.int\/mediacentre\/factsheets\/fs360\/en\/<\/ext-link>."},{"key":"ref2","year":"2013"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/QCO.0b013e3283422cdf","article-title":"Protease inhibitor monotherapy","volume":"24","author":"I Perez-Valero","year":"2011","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jac\/dkr199","article-title":"96 week results from the MONET trial: a randomized comparison of darunavir\/ritonavir with versus without nucleoside analogues, for patients with HIV RNA &lt;50 copies\/mL at baseline","volume":"66","author":"N Clumeck","year":"2011","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"15","key":"ref5","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/QAD.0b013e32833dec20","article-title":"Efficacy of darunavir\/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136","volume":"24","author":"C Katlama","year":"2010","journal-title":"Aids"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1468-1293.2012.00989.x","article-title":"The MONET trial: week 144 analysis of the efficacy of darunavir\/ritonavir (DRV\/r) monotherapy versus DRV\/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load &lt; 50 HIV-1 RNA copies\/mL at baseline","volume":"13","author":"JR Arribas","year":"2012","journal-title":"HIV Med"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/QAI.0b013e3181a56de5","article-title":"Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis","volume":"51","author":"JR Arribas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9709","key":"ref8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(09)62067-5","article-title":"Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial","volume":"375","author":"P Mugyenyi","year":"2010","journal-title":"Lancet"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3851\/IMP2253","article-title":"Lopinavir\/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA)","volume":"17","author":"CF Gilks","year":"2012","journal-title":"Antiviral therapy"},{"key":"ref10","unstructured":"Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, et al. 2013 Update of the Drug Resistance Mutations in HIV-1: March 2013: IAS-USA; 2013. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.iasusa.org\/sites\/default\/files\/tam\/21-1-6.pdf\" xlink:type=\"simple\">http:\/\/www.iasusa.org\/sites\/default\/files\/tam\/21-1-6.pdf<\/ext-link>."},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJMoa1311274","article-title":"Assessment of second-line antiretroviral regimens for HIV therapy in Africa","volume":"371","author":"NI Paton","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1086\/590943","article-title":"Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials","volume":"47","author":"R Gupta","year":"2008","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"Suppl 2","key":"ref13","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1093\/infdis\/jit112","article-title":"Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy\u2014Implications for Sustained Efficacy of ART in Resource-Limited Settings","volume":"207","author":"A Hill","year":"2013","journal-title":"The Journal of infectious diseases"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/QAD.0b013e328353b066","article-title":"Lopinavir\/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings","volume":"26","author":"JA Bartlett","year":"2012","journal-title":"Aids"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/infdis\/jis261","article-title":"Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa","volume":"205","author":"KC Sigaloff","year":"2012","journal-title":"The Journal of infectious diseases"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1742-4690-9-63","article-title":"Human Immunodeficiency Virus Gag and protease: partners in resistance","volume":"9","author":"A Fun","year":"2012","journal-title":"Retrovirology"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/QAD.0b013e3283398216","article-title":"Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays","volume":"24","author":"RK Gupta","year":"2010","journal-title":"Aids"},{"key":"ref18","article-title":"HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir\/ritonavir","author":"KA Sutherland","year":"2014","journal-title":"The Journal of antimicrobial chemotherapy"},{"key":"ref19","article-title":"Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Paediatric Patients","author":"J Giandhari","year":"2015","journal-title":"AIDS research and human retroviruses"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"19784","DOI":"10.7448\/IAS.17.4.19784","article-title":"Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels","volume":"17","author":"SK Pillay","year":"2014","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1086\/648590","article-title":"Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir","volume":"201","author":"N Ndembi","year":"2010","journal-title":"The Journal of infectious diseases"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"W634","DOI":"10.1093\/nar\/gkp455","article-title":"A standardized framework for accurate, high-throughput genotyping of recombinant and non-recombinant viral sequences","volume":"37","author":"LC Alcantara","year":"2009","journal-title":"Nucleic acids research"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1099\/vir.0.055624-0","article-title":"Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B HIV-1","volume":"95","author":"KA Sutherland","year":"2014","journal-title":"The Journal of general virology"},{"issue":"18","key":"ref24","doi-asserted-by":"crossref","first-page":"9094","DOI":"10.1128\/JVI.02356-08","article-title":"Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1","volume":"83","author":"CM Parry","year":"2009","journal-title":"Journal of virology"},{"issue":"12","key":"ref25","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/molbev\/mst197","article-title":"MEGA6: Molecular Evolutionary Genetics Analysis version 6.0","volume":"30","author":"K Tamura","year":"2013","journal-title":"Molecular biology and evolution"},{"issue":"7","key":"ref26","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1177\/135965350601100708","article-title":"Compensatory mutations at the HIV cleavage sites p7\/p1 and p1\/p6-gag in therapy-naive and therapy-experienced patients","volume":"11","author":"J Verheyen","year":"2006","journal-title":"Antiviral therapy"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1128\/JVI.72.9.7632-7637.1998","article-title":"Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients","volume":"72","author":"F Mammano","year":"1998","journal-title":"Journal of virology"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jinf.2006.06.012","article-title":"Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients","volume":"54","author":"I Malet","year":"2007","journal-title":"J Infect"},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/cir131","article-title":"Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy","volume":"52","author":"M Gandhi","year":"2011","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/QAI.0b013e31820dc0cc","article-title":"Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting","volume":"56","author":"GU van Zyl","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref31","article-title":"Phenotypic characterization of virological failure following lopinavir\/ritonavir monotherapy using full-length gag-protease genes","author":"KA Sutherland","year":"2014","journal-title":"The Journal of antimicrobial chemotherapy"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1371\/journal.pmed.0040036","article-title":"A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism","volume":"4","author":"M Nijhuis","year":"2007","journal-title":"PLoS medicine"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.01228-10","article-title":"Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity","volume":"55","author":"CM Parry","year":"2011","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"e1000345","DOI":"10.1371\/journal.ppat.1000345","article-title":"Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss","volume":"5","author":"E Dam","year":"2009","journal-title":"PLoS pathogens"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/QAI.0b013e3181b4b18c","article-title":"Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors","volume":"52","author":"P Jinnopat","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"ref36","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1172\/JCI67399","article-title":"Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance","volume":"123","author":"SA Rabi","year":"2013","journal-title":"The Journal of clinical investigation"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0157094","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T00:00:00Z","timestamp":1464825600000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0137834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T20:51:42Z","timestamp":1653166302000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0137834"}},"subtitle":[],"editor":[{"given":"Carlo Federico","family":"Perno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,18]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0137834","relation":{"correction":[{"id-type":"doi","id":"10.1371\/journal.pone.0157094","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,18]]}}}